CMCarola Muñoz-Montesino

Carola Muñoz-Montesino

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Carola Muñoz-Montesino has a total of 110 co-authors. Here are the top co-authors by number of shared publications:

  • Eduardo Peña

    Departamento de Fisiopatología, Facultad de Ciencias Biológicas, Universidad de Concepción, Concepción, Chile

    6 shared publications
  • Francisco J. Roa

    Departamento de Fisiopatología, Facultad de Ciencias Biológicas, Universidad de Concepción, Concepción, Chile

    6 shared publications
  • Gustavo Moraga-Cid

    Departamento de Fisiologia, Facultad de Ciencias Biologicas, Universidad de Concepcion, Concepcion, Chile

    6 shared publications
  • Juan Carlos Vera

    Departamento de Fisiopatología, Facultad de Ciencias Biológicas, Universidad de Concepción, Barrio Universitario s/n, PO Box 160C, Concepción, Chile

    6 shared publications
  • Coralia I. Rivas

    Departamento de Fisiopatología, Facultad de Ciencias Biológicas, Universidad de Concepción, Barrio Universitario s/n, PO Box 160C, Concepción, Chile

    5 shared publications
  • Kirsty Sotomayor

    Departamento de Fisiopatología, Facultad de Ciencias Biológicas, Universidad de Concepción, Concepción, Chile

    5 shared publications

Latest Publications

  • Open Access

    Cysteine residues located within the core domain of human vitamin C transporter, hSVCT2, are essential for its structural and functional properties

    by Marcell Gatica, Carlos Aylwin, Karen Sweet, Alejandra Muñoz, Alejandro M. Reyes, Carlos F. Burgos, Juan Carlos Vera, Carola Muñoz-Montesino, Coralia I. Rivas

  • Open Access

    TG2 promotes amyloid beta aggregates: Impact on ER-mitochondria crosstalk, calcium homeostasis and synaptic function in Alzheimer’s disease

    by Jessica Panes-Fernandez, Pamela A. Godoy, Javiera Gavilan, Oscar Ramírez-Molina, Carlos Felipe Burgos, Ana Marileo, Oscar Flores-Núñez, Patricio A. Castro, Gustavo Moraga-Cid, Gonzalo E. Yévenes, et al.


  • Open Access

    PrPC as a Transducer of Physiological and Pathological Signals

    by Jessica D. Panes, Paulina Saavedra, Benjamin Pineda, Kathleen Escobar, Magdalena E. Cuevas, Gustavo Moraga-Cid, Jorge Fuentealba, Coralia I. Rivas, Human Rezaei, Carola Muñoz-Montesino

    After the discovery of prion phenomenon, the physiological role of the cellular prion protein (PrPC) remained elusive. In the past decades, molecular and cellular analysis has shed some light regarding interactions and functions of PrPC in health and disease. PrPC, which is located mainly at the plasma membrane of neuronal cells attached by a glycosylphosphatidylinositol (GPI) anchor, can act as a receptor or transducer from external signaling. Although the precise role of PrPC remains elusive, a variety of functions have been proposed for this protein, namely, neuronal excitability and viability. Although many issues must be solved to clearly define the role of PrPC, its connection to the central nervous system (CNS) and to several misfolding-associated diseases makes PrPC an interesting pharmacological target. In a physiological context, several reports have proposed that PrPC modulates synaptic transmission, interacting with various proteins, namely, ion pumps, channels, and metabotropic receptors. PrPC has also been implicated in the pathophysiological cell signaling induced by β-amyloid peptide that leads to synaptic dysfunction in the context of Alzheimer’s disease (AD), as a mediator of Aβ-induced cell toxicity. Additionally, it has been implicated in other proteinopathies as well. In this review, we aimed to analyze the role of PrPC as a transducer of physiological and pathological signaling.


  • Transport of Vitamin C in Cancer

    by Carola Muñoz-Montesino, Eduardo Peña, Francisco J. Roa, Kirsty Sotomayor, Elizabeth Escobar, Coralia I. Rivas

    Significance: Vitamin C is a powerful antioxidant that has an intricate relationship with cancer and has been studied for more than 60 years. However, the specific mechanisms that allow malignant cells to uptake, metabolize, and compartmentalize vitamin C remain unclear. In normal human cells, two different transporter systems are responsible for its acquisition: glucose transporters (GLUTs) transport the oxidized form of vitamin C (dehydroascorbic acid) and sodium-coupled ascorbic acid transporters (SVCTs) transport the reduced form (ascorbic acid [AA]). In this study, we review the mechanisms described for vitamin C uptake and metabolization in cancer. Recent Advances: Several studies performed recently in vivo and in vitro have provided the scientific community a better understanding of the differential capacities of cancer cells to acquire vitamin C: tumors from different origins do not express SVCTs in the plasma membrane and are only able to acquire vitamin C in its oxidized form. Interestingly, cancer cells differentially express a mitochondrial form of SVCT2. Critical Issues: Why tumors have reduced AA uptake capacity at the plasma membrane, but develop the capacity of AA transport within mitochondria, remains a mystery. However, it shows that understanding vitamin C physiology in tumor survival might be key to decipher the controversies in its relationship with cancer. Future Directions: A comprehensive analysis of the mechanisms by which cancer cells acquire, compartmentalize, and use vitamin C will allow the design of new therapeutic approaches in human cancer. Antioxid. Redox Signal. 35, 61–74.


  • Open Access

    Complex Interaction between Resident Microbiota and Misfolded Proteins: Role in Neuroinflammation and Neurodegeneration

    by Juliana González-Sanmiguel, Christina M. A. P. Schuh, Carola Muñoz-Montesino, Pamina Contreras-Kallens, Luis G. Aguayo, Sebastian Aguayo

    Neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Creutzfeldt–Jakob disease (CJD) are brain conditions affecting millions of people worldwide. These diseases are associated with the presence of amyloid-β (Aβ), alpha synuclein (α-Syn) and prion protein (PrP) depositions in the brain, respectively, which lead to synaptic disconnection and subsequent progressive neuronal death. Although considerable progress has been made in elucidating the pathogenesis of these diseases, the specific mechanisms of their origins remain largely unknown. A body of research suggests a potential association between host microbiota, neuroinflammation and dementia, either directly due to bacterial brain invasion because of barrier leakage and production of toxins and inflammation, or indirectly by modulating the immune response. In the present review, we focus on the emerging topics of neuroinflammation and the association between components of the human microbiota and the deposition of Aβ, α-Syn and PrP in the brain. Special focus is given to gut and oral bacteria and biofilms and to the potential mechanisms associating microbiome dysbiosis and toxin production with neurodegeneration. The roles of neuroinflammation, protein misfolding and cellular mediators in membrane damage and increased permeability are also discussed.


  • Open Access

    A seven-residue deletion in PrP leads to generation of a spontaneous prion formed from C-terminal C1 fragment of PrP

    by Carola Munoz-Montesino, Djabir Larkem, Clément Barbereau, Angélique Igel-Egalon, Sandrine Truchet, Eric Jacquet, Naïma Nhiri, Mohammed Moudjou, Christina Sizun, Human Rezaei, et al.


  • Open Access

    Therapeutic Use of Vitamin C in Cancer: Physiological Considerations

    by Francisco J. Roa, Eduardo Peña, Marcell Gatica, Kathleen Escobar-Acuña, Paulina Saavedra, Mafalda Maldonado, Magdalena E. Cuevas, Gustavo Moraga-Cid, Coralia I. Rivas, Carola Muñoz-Montesino

    Since the early studies of William J. McCormick in the 1950s, vitamin C has been proposed as a candidate for the treatment of cancer. A number of reports have shown that pharmacological concentrations of vitamin C selectively kill cancer cells in vitro and decrease the growth rates of a number of human tumor xenografts in immunodeficient mice. However, up to the date there is still doubt regarding this possible therapeutic role of vitamin C in cancer, mainly because high dose administration in cancer patients has not showed a clear antitumor activity. These apparent controversial findings highlight the fact that we lack information on the interactions that occurs between cancer cells and vitamin C, and if these transformed cells can uptake, metabolize and compartmentalize vitamin C like normal human cells do. The role of SVCTs and GLUTs transporters, which uptake the reduced form and the oxidized form of vitamin C, respectively, has been recently highlighted in the context of cancer showing that the relationship between vitamin C and cancer might be more complex than previously thought. In this review, we analyze the state of art of the effect of vitamin C on cancer cells in vitro and in vivo, and relate it to the capacity of cancer cells in acquiring, metabolize and compartmentalize this nutrient, with its implications on the potential therapeutic role of vitamin C in cancer.


  • Open Access

    Data on SVCT2 transporter expression and localization in cancer cell lines and tissues

    by Francisco J. Roa, Eduardo Peña, Eveling Inostroza, Kirsty Sotomayor, Mauricio González, Francisco A. Gutierrez-Castro, Michelle Maurin, Karen Sweet, Claire Labrousse, Marcell Gatica, et al.


  • Increased expression of mitochondrial sodium-coupled ascorbic acid transporter-2 (mitSVCT2) as a central feature in breast cancer

    by Eduardo Peña, Francisco J. Roa, Eveling Inostroza, Kirsty Sotomayor, Mauricio González, Francisco A. Gutierrez-Castro, Michelle Maurin, Karen Sweet, Claire Labrousse, Marcell Gatica, et al.


  • Large Intracellular Domain-Dependent Effects of Positive Allosteric Modulators on Glycine Receptors

    by Cesar O. Lara, Carlos F. Burgos, Tiare Silva-Grecchi, Carola Muñoz-Montesino, Luis G. Aguayo, Jorge Fuentealba, Patricio A. Castro, Jose L. Guzmán, Pierre-Jean Corringer, Gonzalo E. Yévenes, et al.

    Glycine receptors (GlyRs) are members of the pentameric ligand-gated ionic channel family (pLGICs) and mediate fast inhibitory neurotransmission in the brain stem and spinal cord. The function of GlyRs can be modulated by positive allosteric modulators (PAMs). So far, it is largely accepted that both the extracellular (ECD) and transmembrane (TMD) domains constitute the primary target for many of these PAMs. On the other hand, the contribution of the intracellular domain (ICD) to the PAM effects on GlyRs remains poorly understood. To gain insight about the role of the ICD in the pharmacology of GlyRs, we examined the contribution of each domain using a chimeric receptor. Two chimeras were generated, one consisting of the ECD of the prokaryotic homologue GLIC fused to the TMD of the human 1GlyR lacking the ICD (Lily) and a second with the ICD (Lily-ICD). The sensitivity to PAMs of both chimeric receptors was studied using electrophysiological techniques. The Lily receptor showed a significant decrease in the sensitivity to four recognized PAMs. Remarkably, the incorporation of the ICD into the Lily background was sufficient to restore the wild-type α1GlyR sensitivity to these PAMs. Based on these data, we can suggest that the ICD is necessary to form a pLGIC having full sensitivity to positive allosteric modulators.